(Reuters) - Regeneron Pharmaceuticals Inc on Monday said it has received notice that Sanofi SA intends to acquire Regeneron's common stock through open market purchases and direct purchases from shareholders.
As a result, SANOFI (SAN.PA)intends that the value of its ownership of voting securities of Regeneron stock will be above the $500 million Hart-Scott-Rodino Act notification threshold, Regeneron said.
Neither company could immediately be reached for comment
The two companies have a longstanding agreement to develop medicines together, including promising treatments for cholesterol and arthritis.
Regeneron is best known for its blockbuster drug Eylea for macular degeneration, which it owns alone.
(Reporting By Debra Sherman; Editing by Gerald E. McCormick)
Relacionados
- Planas incide en priorizar respecto al gasoducto de Doñana la defensa de "la primera reserva ecológica europea"
- Del Río destaca el uso del número de emergencias 112 en la Unión Europea y en países no comunitarios como Estados Unidos
- La banca europea podría tomarse un merecido descanso
- La Comisión Europea se plantea prohibir los vertederos urbanos
- Un director de la Agencia Espacial Europea apuesta por la vida extraterrestre
